Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 30, 2026 11:30 ET | Source: Confo Therapeutics

Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554

Confo Therapeutics announces the Phase 2a clinical trial initiation by Eli Lilly and Company for CFTX-1554 in peripheral pain.
April 29, 2026 07:00 ET | Source: EnteroBiotix

EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for Irritable Bowel Syndrome

Funds will support one of the largest interventional clinical trials of a full-spectrum microbiome product, and the largest ever to be conducted in IBSDosing of first patient of the Phase 2b ‘RISE’...
April 29, 2026 03:00 ET | Source: EnteroBiotix

EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for Irritable Bowel Syndrome

Funds will support one of the largest interventional clinical trials of a full-spectrum microbiome product, and the largest ever to be conducted in IBSDosing of first patient of the Phase 2b ‘RISE’...
April 28, 2026 08:30 ET | Source: Prodeon Medical

Prodeon Medical Highlights the Urocross Expander System Clinical Results at the American Urological Association (AUA) 2026 Annual Meeting

Prodeon at AUA 2026: Urocross Expander pivotal RCT to be presented at the plenary: 30-month data shows durable BPH relief and preserved sexual function
April 24, 2026 08:00 ET | Source: Kyowa Kirin

Kyowa Kirin and Kura Oncology Initiate Japanese Phase 2 Registration-Directed Trial of Ziftomenib in R/R NPM1-m AML

TOKYO and SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) -- Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced the first patient has been...
April 24, 2026 01:47 ET | Source: Clinuvel Pharmaceuticals Limited

CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study

EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its “totality of evidence” approachcentral photographic review and validated disease...
April 23, 2026 12:14 ET | Source: PridCor Therapeutics, LLC

PridCor Therapeutics Secures Global Antiviral Portfolio, Establishing Leadership in Treatment of Long COVID and Infection-Associated Chronic Illnesses

PridCor secures global antiviral portfolio with Phase 2b and Phase 3 assets to advance treatments for Long COVID and chronic illness.
April 23, 2026 07:00 ET | Source: Psyence Biomedical Ltd.

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a clinical-stage biopharmaceutical company developing nature-derived...
April 23, 2026 04:00 ET | Source: Nectero Therapeutics

Nectero Therapeutics Reports Two-Year Safety and Efficacy Data from First-in-Human Trial for Treatment of Small- to Medium-Sized Abdominal Aortic Aneurysms

LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Nectero Therapeutics, a clinical-stage biotechnology company developing therapies for aneurysmal disease, released two-year outcomes data today from the...
April 22, 2026 16:00 ET | Source: INVENTIVA

Inventiva Strengthens Leadership Team Ahead of Expected Phase 3 Data Readout of Lanifibranor

Recruitment of Chief Financial Officer, Chief Legal Officer, and Chief People Officer reflects Inventiva’s organizational build-out as it advances toward potential commercialization.Axel-Sven Malkomes...